Recombinant factor VIIa enhances deposition of platelets with congenital or acquired αIIbβ3 deficiency to endothelial cell matrix and collagen under conditions of flow via tissue factor-independent thrombin generation

Blood

Volumn 101, Issue 5, 2003, Pages 1864-1870

  Lisman, Ton ^a   Moschatsis, Sultana ^b   Adelmeijer, Jelle ^b   Karel Nieuwenhuis, H ^b   De Groot, Philip G ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; COLLAGEN; EPTIFIBATIDE; INTEGRIN; LIPOCORTIN 5; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; THROMBIN; THROMBOPLASTIN; TIROFIBAN;

ARTICLE; BLEEDING; CONTROLLED STUDY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; GLANZMANN DISEASE; HEMOSTASIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOSIS;

EID: 0037372315     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2761     Document Type: Article

References (34)

1. Parise LV, Smyth SS, Coller BS. Platelet morphology, biochemistry and function. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ, Seligsohn U, eds. Williams Hematology. New York, NY: McGraw-Hill, 2001:1357-1408.
2. French DL, Seligsohn U. Platelet glycoprotein IIb/IIIa receptors and Glanzmann's thrombasthenia. Arterioscler Thromb Vasc Biol. 2000;20:607-610.
3. Coller BS. Anti-GPIIb/IIIa drugs: current strategies and future directions. Thromb Haemost. 2001;86:427-443.
4. Tcheng JE. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J. 2000;139:S38-S45.
5. Poon MC, Demers C, Jobin F, Wu JW. Recombinant factor VIIa is effective for bleeding and surgery in patients with Glanzmann thrombasthenia. Blood. 1999;94:3951-3953.
6. Poon MC, d'Oiron R, Hann I, et al. Use of recombinant factor VIIa (NovoSeven) in patients with Glanzmann thrombasthenia. Semin Hematol. 2001;38:21-25.
7. Hedner U, Glazer S, Pingel K, et al. Successful use of recombinant factor VIIa in a patient with severe haemophilia A during synovectomy [letter]. Lancet. 1988;8621:1193.
8. Ingerslev J. Efficacy and safety of recombinant factor VIIa in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost. 2000;26:425-432.
9. Hendriks HG, Meijer K, de Wolf JT, et al. Reduced transfusion requirements by recombinant factor VIIa in orthotopic liver transplantation: a pilot study. Transplantation. 2001;71:402-405.
10. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. Gastroenterology. 1997;113:1930-1937.
11. Kristensen J, Killander A, Hippe E, et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. Haemostasis. 1996;26(suppl 1):159-164.
12. Peters M, Heijboer H. Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa. Thromb Haemost. 1998;80:352-352.
13. Friederich PW, Geerdink MGF, Spataro M, et al. The effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) on perioperative blood loss in patients undergoing transabdominal retropubic prostatectomy: the PROSE study. Blood Coag Fibrinol. 2000;11: s129-s132.
14. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa [letter]. Lancet. 1999;354:1879.
15. Stepinska J, Banaszewski M, Konopka A, Szajewski T. Activated recombinant factor VII (rFVIIa) in bleeding management after therapy with IIb/IIIa-inhibitor tirofiban. Thromb Haemost. 2002;87:355-356.
16. van't Veer C, Golden NJ, Mann KG. Inhibition of thrombin generation by the zymogen factor VII: implications for the treatment of hemophilia A by factor VIIa. Blood. 2000;95:1330-1335.
17. Lisman T, Mosnier LO, Lambert T, et al. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe haemophilia A. Blood. 2002;99:175-179.
18. ten Cate H, Bauer KA, Levi M, et al. The activation of factor X and prothrombin by recombinant factor VIIa in vivo is mediated by tissue factor. J Clin Invest. 1993;92:1207-1212.
19. Monroe DM, Hoffman M, Olivier JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol. 1997;99:542-547.
20. Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. Semin Thromb Hemost. 2000;26:373-377.
21. De Marco L, Mazzucato M, Masotti A, Ruggeri ZM. Localization and characterization of an alpha-thrombin-binding site on platelet glycoprotein lb alpha. J Biol Chem. 1994;269:6478-6484.
22. Dormann D, Clemetson KJ, Kehrel BE. The GPIb thrombin-binding site is essential for thrombin-induced platelet procoagulant activity. Blood. 2000;96:2469-2478.
23. De Candia E, Hall SW, Rutella S, Landolfi R, Andrews RK, De Cristofaro R. Binding of thrombin to glycoprotein lb accelerates the hydrolysis of Par-1 on intact platelets. J Biol Chem. 2001;276:4692-4698.
24. Ramakrishnan V, Reeves PS, DeGuzman F, et al. Increased thrombin responsiveness in platelets from mice lacking glycoprotein V. Proc Natl Acad Sci U S A. 1999;96:13336-13341.
25. Ramakrishnan V, DeGuzman F, Bao M, Hall SW, Leung LL, Phillips DR. Athrombin receptor function for platelet glycoprotein lb-IX unmasked by cleavage of glycoprotein V. Proc Natl Acad Sci U S A. 2001;98:1823-1828.
26. Kahn ML, Nakanishi-Matsul M, Shapiro MJ, Ishihara H, Coughlin SR. Protease-activated receptors 1 and 4 mediate activation of human platelets by thrombin. J Clin Invest. 1999;103:879-887.
27. Hackeng TM, van't Veer C, Meijers JC, Bouma BN. Human protein S inhibits prothrombinase complex activity on endothelial cells and platelets via direct interactions with factors Va and Xa. J Biol Chem. 1994;269:21051-21058.
28. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest. 1988;82:1236-1243.
29. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745-2756.
30. Sixma JJ, de Groot PG, van Zanten H, IJsseidijk M. A new perfusion chamber to detect platelet adhesion using a small volume of blood. Thromb Res. 1998;92:S43-S46.
31. Sakariassen KS, Aarts PAMM, de Groot PG, Houdijk WPM, Sixma JJ. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel walls, their extracellular matrix, and purified components. J Lab Clin Med. 1983;102:522-535.
32. Hoffman M, Monroe DM, Roberts HR. Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. Blood. 1994;83:38-42.
33. Zwaginga JJ, Sixma JJ, de Groot PG. Activation of endothelial cells induces platelet thrombus formation on their matrix. Arteriosclerosis. 1990;10:49-61.
34. Galan AM, Reverter JC, Pino M, Lozano M, Ordinas A, Escolar G. Increased local procoagulant action: a mechanism contributing to the favourable hemostatic effect of activated recombinant factor VII (rFVIIa) in quanti and qualitative disorders of platelet function [abstract]. Thromb Haemost 2001;86:P1156a.